News
RIGL
42.05
+6.05%
2.40
Rigel Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 7h ago
Rigel Pharmaceuticals Price Target Raised to $86.00/Share From $83.00 by Citigroup
Dow Jones · 7h ago
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $86
Benzinga · 8h ago
Cantor Fitzgerald Reaffirms Their Hold Rating on Rigel (RIGL)
TipRanks · 12h ago
Citi Keeps Their Buy Rating on Rigel (RIGL)
TipRanks · 15h ago
Rigel Pharmaceuticals price target raised to $86 from $83 at Citi
TipRanks · 15h ago
Weekly Report: what happened at RIGL last week (1102-1106)?
Weekly Report · 16h ago
Rigel Pharmaceuticals Down Over 11%, on Pace for Largest Percent Decrease Since September 2025 -- Data Talk
Dow Jones · 3d ago
Rigel Pharmaceuticals Price Target Raised to $47.00/Share From $43.00 by Cantor Fitzgerald
Dow Jones · 3d ago
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 3d ago
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47
Benzinga · 3d ago
Rigel (RIGL) Q3 2026 Earnings Call Transcript
The Motley Fool · 3d ago
Rigel Pharmaceuticals narrows 2026 revenue view to $290M-$295M from $285M-$295M
TipRanks · 4d ago
Rigel Pharmaceuticals reports Q3 EPS 65c, consensus 96c
TipRanks · 4d ago
Rigel’s R289 Clinical Update and Tavalisse Data Support Buy Rating; Price Target Unchanged at $85
TipRanks · 5d ago
Rigel reports data from Phase 1b clinical study of R2891
TipRanks · 5d ago
United Therapeutics (UTHR) Q3 Earnings Miss Estimates
NASDAQ · 5d ago
Weekly Report: what happened at RIGL last week (1026-1030)?
Weekly Report · 11/02 10:15
What Rigel Pharmaceuticals Holders Saw Early
Simply Wall St · 10/31 19:28
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
PR Newswire · 10/29 12:05
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.